Glycan-interacting compounds and methods of use

Abstract

The present invention provides glycan-interacting antibodies and methods for producing glycan-interacting antibodies useful in the treatment and prevention of human disease, including cancer. Such glycan-interacting antibodies include monoclonal antibodies, derivatives, and fragments thereof as well as compositions and kits comprising them. Further provided are methods of using glycan-interacting antibodies to target cells and treat disease.

1 - 7 . (canceled) 
     
     
         8 . An antibody comprising:
 (a) a CDR-L1 selected from the group consisting of SEQ ID NOs: 100-114, and SEQ ID NOs: 159-167;   (b) a CDR-L2 selected from the group consisting of SEQ ID NOs: 115-126, and SEQ ID NOs: 168-170;   (c) a CDR-L3 selected from the group consisting of SEQ ID NOs: 127-142, and SEQ ID NOs: 171-173;   (d) a CDR-H1 selected from the group consisting of SEQ ID NOs: 81-83, SEQ ID NO: 143, and SEQ ID NO: 144;   (e) a CDR-H2 selected from the group consisting of SEQ ID NOs: 84-89, and SEQ ID NOs: 145-151; and   (f) a CDR-H3 selected from the group consisting of SEQ ID NOs: 90-99, and SEQ ID NOs: 152-158.   
     
     
         9 . The antibody of  claim 8 , comprising a monoclonal antibody. 
     
     
         10 . The antibody of any of  claim 8 , wherein said antibody comprises an IgG isotype. 
     
     
         11 - 16 . (canceled) 
     
     
         17 . The antibody of  claim 10 , wherein said antibody comprises an antibody-drug conjugate. 
     
     
         18 . (canceled) 
     
     
         19 . The antibody of  claim 17 , wherein said antibody-drug conjugate comprises a cytotoxic agent. 
     
     
         20 . (canceled) 
     
     
         21 . The antibody of  claim 19 , wherein said cytotoxic agent is conjugated to said antibody via a linker. 
     
     
         22 - 23 . (canceled) 
     
     
         24 . The antibody of  claim 21 , wherein said cytotoxic agent is a cytoskeletal inhibitor. 
     
     
         25 - 27 . (canceled) 
     
     
         28 . A method of treating cancer in a subject in need thereof, said method comprising administering to said subject the antibody of claim  22 . 
     
     
         29 . The method of  claim 28 , wherein said cancer comprises an epithelial cancer. 
     
     
         30 . The method of  claim 29 , wherein said epithelial cancer comprises breast, colon, lung, bladder, cervical, ovarian, stomach, prostate, and/or liver cancer. 
     
     
         31 - 62 . (canceled) 
     
     
         63 . A method of identifying cancerous cells in a tissue or organ comprising the use of the antibody of claim  1 . 
     
     
         64 . The method of  claim 63 , wherein said tissue or organ is selected from the group consisting of breast, ovary, and pancreas. 
     
     
         65 - 75 . (canceled) 
     
     
         76 . The method of  claim 63 , wherein said antibody comprises a variable domain pair selected from the group consisting of:
 SEQ ID NO:15 and SEQ ID NO:16;   SEQ ID NO:17 and SEQ ID NO:18;   SEQ ID NO:19 and SEQ ID NO:20;   SEQ ID NO:21 and SEQ ID NO:22;   SEQ ID NO:23 and SEQ ID NO:24;   SEQ ID NO:25 and SEQ ID NO:26;   SEQ ID NO:27 and SEQ ID NO:28;   SEQ ID NO:29 and SEQ ID NO:30;   SEQ ID NO:31 and SEQ ID NO:32;   SEQ ID NO:35 and SEQ ID NO:36;   SEQ ID NO:37 and SEQ ID NO:38;   SEQ ID NO:39 and SEQ ID NO:40;   SEQ ID NO:42 and SEQ ID NO:32;   SEQ ID NO:44 and SEQ ID NO:45;   SEQ ID NO:46 and SEQ ID NO:32;   SEQ ID NO:47 and SEQ ID NO:32;   SEQ ID NO:48 and SEQ ID NO:50;   SEQ ID NO:48 and SEQ ID NO:49; and   SEQ ID NO:51 and SEQ ID NO:52.   
     
     
         77 . The method of  claim 28 , wherein said antibody comprises at least one human framework region from a human donor antibody. 
     
     
         78 . The method of  claim 28 , wherein said antibody is a humanized antibody. 
     
     
         79 . The method of  claim 78 , wherein said antibody is prepared by CDR-grafting. 
     
     
         80 . The method of  claim 78 , wherein said cytotoxic agent comprises monomethyl auristatin E (MMAE).